The device rapidly reduces the parasitaemia of severe Malaria patients who have been hospitalised and prescribed IV drug treatment.

While there are effective pharmaceutical treatments available, disease severity, recovery times and mortality are all strongly linked to a patient’s parasitaemia upon beginning drug treatment. Given the lengthy travel time required for many developing world patients to reach hospital many only get treatment once it’s too late. The key to tackling malaria lies in our ability to facilitate the rapid removal of infected red blood cells. When this is successfully carried out, a significant reduction of parasitaemia occurs – and that signifies the first steps on a patient's road to recovery.

Broad risk groups

Under 5s

Pregnant

Immune deficient patients

Significant worldwide burden

200k annual infant deaths

50% of the world at risk

Severe malaria high morbidity and mortality

Mortality rate 20%

Coma

Respiratory distress

Growing resistance to current treatment

Antibiotic resistance

Mosquito resistance to insecticides

Increasing cases

Pre-clinical results appear to be very encouraging, indicating that the MediSieve Filter could reduce a child's parasitaemia by over 90% in two hours. Magnetic haemofiltration offers the chance to turn back the clock for these patients by rapidly and safely reducing a patient’s parasitaemia. A one-off treatment of a severe patient could reduce mortality, accelerate symptom reduction, and prevent disease escalation.

Latest News

MediSieve Receives Approval for First-in-Man Clinical Investigation

MediSieve Receives Approval for First-in-Man Clinical Investigation
May 24, 2022

Radboud University Medical Center will perform the first trial of the Novel Magnetic Haemoflitration System.
MediSieve Receives Industry Recognition

MediSieve Receives Industry Recognition
April 02, 2022

MediSieve, a biotech company that has developed an innovative blood filtration device, receives recognition and approval from the industry.